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A B S T R A C T
Medicinal plants and herbal extracts from traditional Chinese medicine are used increasingly commonly
worldwide for their beneﬁts to health and quality of life as dietary supplements or as ingredients in functional
foods. Among them, Salvia miltiorrhiza Bunge (a natural strong remedy for the treatment of a variety of con-
ditions) is traditionally used for centuries in Asian countries as antioxidant, anticancer, and anti-inﬂammatory
agent. In this context, several evidences support the hypothesis that some tanshinones (in particular tanshinone
IIA and cryptotanshinone) extracted from the roots (Danshen) of Salvia miltiorrhiza exert neuroprotective and
analgesic activities.
Oxaliplatin (OXA), a platinum-based drug used for the treatment of solid tumors, induces neuropathic pain
which hampers the chemotherapy success. While several attempts were made to prevent oxaliplatin-induced
painful neuropathy, a growing number of evidences look to natural sources as an eﬀective remedy to counter-
balance the OXA-mediated side eﬀects.
The aim of the present study was to investigate the pain-relieving proﬁle of Danshen and its active con-
stituents tanshinone IIA (TIIA) and cryptotanshinone (CRY) in animal models of neuropathic pain induced by
OXA, anticancer drug characterized by a dose-limiting neurotoxicity. Contextually, the neuroprotective and
anticancer activities of the selected compounds were tested in diﬀerent cells lines. A single administration per os
of CRY (30mg mg/kg) signiﬁcantly, in a dose dependent manner, attenuated chemotherapy-induced pain. A 7
days repeated administrations highlighted the eﬀectiveness and potency of both CRY and TIIA (10mg/kg). On
the other hand, Danshen showed a painkiller proﬁle against oxaliplatin-induced neuropathy. Contextually,
Danshen and its active constituents showed remarkable and selective inhibitory activities on glioblastoma cells
lines LN-229 (IC50: 50.0 ± 4.0, 48.2 ± 4.9 and 51.9 ± 2.3 μM respectively for Danshen standardized extract,
TIIA and CRY) next to healthy but high proliferative cell lines enterocytes (IC50:> 250 μM for TIIA and CRY) and
keratinocytes (IC50:> 100 and 97 ± 2 μM respectively for TIIA and CRY).
Taken together the results reported here demonstrated the long-lasting pain-relieving eﬀects of Danshen and
its related bioactive constituents in animal models of neuropathic pain and their selective in vitro neuroprotective
properties on certain central malignancy cells lines. Thus, suggest that S. miltiorrhiza roots could be considered as
a new potential source of active diterpenoidic compounds useful for pharmaceutical or nutraceutical industries
and beneﬁcial as food complements.
1. Introduction
Patients treated with platinum-based chemotherapy in diﬀerent
forms of solid tumors (colorectal, lung, breast and ovarian) frequently
experience neurotoxic symptoms such as a distal dose-dependent sym-
metrical sensory neuropathy, which may lead to premature dis-
continuation of therapy [1,2]. These symptoms become evident when
cumulative oxaliplatin-based dose has administrated [3], even if it has
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been observed that in the 90% of patients in treatment with oxaliplatin
(OXA) it also causes acute dose-independent neurotoxicity [4]. The
acute and chronic forms display speciﬁc symptom proﬁle. Acute OXA
neurotoxicity is cold-induced or cold-aggravated, characterized by
speciﬁc distal sensory symptoms such as paresthesias and dysesthesias
[5], whereas the chronic form is characterized by distal sensory ataxia,
and occurs at a level suﬃcient to cause patients functional impairment
[6].
Therefore, developing treatment regimens ideally with superior ef-
fectiveness and minimal adverse eﬀects for these conditions remain a
priority in cancer research pushing researchers to investigate new and
more reliable potential therapeutic strategies. Contextually, investiga-
tion on traditional medicinal plants as ingredients in functional and
health care foods routinely used and/or prescribed together with con-
ventional therapy in clinical practice is another deal of international
scientiﬁc community aimed to improve the eﬀectiveness of che-
motherapeutics in the prevention and/or treatment of cancer and
cancer-related side eﬀects [7,8].
In this contest, one of the potential alternative could be represented
by Salvia miltiorrhiza Bunge, a perennial herb belongs to Labiatae family
[9]. Its dry root and/or rhizome, commonly known as Danshen in
Chinese, is oﬃcially listed in the Chines Pharmacopoeia [10]. Due to its
diverse pharmacologic properties, is categorized as one of the main
commercial herbs in this country. In line, pharmacological research’s
indicate that diterpenoidic like compounds such as TIIA and CRY from
Danshen exhibited remarkable properties for the treatment of cardio-
vascular [11,12,13,14], cerebrovascular [15,16], inﬂammatory dis-
eases [17,18] and cancer [19,20,21].
Recent clinical studies have also demonstrated that Danshen im-
proves survival of patients by inhibiting the proliferation of colon
cancer cells [22]. Lately, the eﬃcacy of TIIA in chemotherapy-induced
painful neuropathy was suggested since Xu et al. [23] demonstrated the
eﬃcacy of this Danshen-derived compound in relieving pain and im-
proving neurophysiological functions in patients (II-III phase) with
malignant tumor of digestive tract undergoing chemotherapy program
with OXA. Furthermore, Danshen and tanshinones prevent neurotoxi-
city and neurodegeneration in PC12 cells, human neuroblastoma and
nigrostriatal dopaminergic neurons [24,25,26]. It has also been shown
that TIIA rescues the impairments of astrocytes and spinal cord neurons
after ischemic insults and inﬂammatory traumatic injury [27,28] and
that attenuates neuropathic pain via inhibiting glial activation and
immune response [29].
Despite the potential of Danshen-related tanshinones as a neuro-
protective agent, no experimental study has been conducted to de-
termine their eﬀects in animal models of neuropathic pain induced by
OXA. In addition, the impact on their selective antitumor activity re-
mains unknown. These evidences prompted us to investigate the pain-
relieving proﬁle of standardized extract of Danshen and its active main
constituents (TIIA and CRY) in OXA-related peripheral neuropathy
alongside with the examination of their neuroprotective and anticancer
activities on neuronal and peripheral high-dividing cell lines.
2. Materials and Methods
2.1. Reagents
Cryptotanshinone and tanshinone IIA (≥ 97%, HPLC) were ob-
tained from Sigma–Aldrich Co. (Milan, Italy) whereas Salvia miltiorrhiza
Bunge root dried extract (E.S. 1% tanshinones) from New Phargam
S.R.L. (Milan, Italy). Oxaliplatin was obtained from Carbosynth
(Berkshire, UK).
2.2. Animals
Male CD-1 albino mice (Envigo, Varese, Italy) weighing approxi-
mately 22–25 g at the beginning of the experimental procedure, were
used. Animals were housed in CeSAL (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least 1 week after their
arrival. Ten mice were housed per cage (size 26×41 cm); animals were
fed a standard laboratory diet and tap water ad libitum, and kept at
23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All animal ma-
nipulations were carried out according to the Directive 2010/63/EU of
the European parliament and of the European Union council
(September 22, 2010) on the protection of animals used for scientiﬁc
purposes. The ethical policy of the University of Florence complies with
the Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85-23, revised 1996;
University of Florence assurance number: A5278-01). Formal approval
to conduct the experiments described was obtained from the Animal
Subjects Review Board of the University of Florence. Experiments in-
volving animals have been reported according to ARRIVE guidelines
[30]. All eﬀorts were made to minimize animal suﬀering and to reduce
the number of animals used.
2.3. Oxaliplatin-induced neuropathic pain
Mice were administered intraperitoneally (i.p.) with 2.4 mg/kg ox-
aliplatin (dissolved in 5% glucose solution) on days 1-3, 5-9, and 12-13,
to develop neuropathic pain [31,32]. Control animals received an
equivalent volume of vehicle.
2.4. Compounds administrations
The eﬀects of cryptotanshinone (CRY), tanshinone IIA (TIIA) and
Salvia miltiorrhiza root extract (Danshen) were evaluated acutely after a
single administration per os (p.o.) on day 14 of oxaliplatin treatment.
CRY and TIIA were analyzed also after a repeated treatment: starting
from the ﬁrst day of oxaliplatin treatment, TIIA and CRY were daily
administered p.o. for 14 days, behavioral measurements were per-
formed on days 7 and/or 14, 24 h after the last administration of
compounds.
2.5. Cold plate test
Each animal was placed in a stainless-steel box
(12 cm×20 cm×10 cm) with a cold plate as ﬂoor. The temperature of
the cold plate was kept constant at 4 °C ± 1 °C. Pain-related behavior
(licking of the hind paw) was observed and the time (seconds) of the
ﬁrst sign was recorded. The cut-oﬀ time of the latency of paw lifting or
licking was set at 60 s [32].
2.6. Rota-rod test
The rota-rod test was used to determine the integrity of motor co-
ordination in mice after drug treatment [33]. The apparatus used for
the rota-rod tests consisted of a base platform and a rotating rod with a
diameter of 3 cm and a non-slippery surface. The rod was placed at a
height of 15 cm from the base. The rod, 30 cm in length, was divided
into ﬁve equal sections by six disks. Thus, up to ﬁve mice were tested
simultaneously on the apparatus, with a rod-rotating speed of 16 rpm.
The integrity of motor coordination was assessed on the basis of the
time the animals kept their balance on the rotating rod for a maximum
of 10min (600 s). After a maximum of 6 falls from the rod the test was
suspended and the time was recorded.
2.7. Hole board test
The hole board test was used to determine the spontaneous mobility
(board) and the exploratory activity (hole) of mice after drug treatment.
The apparatus consisted of a 40 cm square plane with 16 ﬂush mounted
cylindrical holes (3 cm diameter) distributed 4×4 in an equidistant,
grid-like manner. Mice were placed on the center of the board one by
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one and allowed to move about freely for a period of 5min each. Two
photobeams, crossing the plane from mid-point to mid-point of opposite
sides, thus dividing the plane into 4 equal quadrants, automatically
signaled the movement of the animal (counts in 5min) on the surface of
the plane (locomotor activity). Miniature photoelectric cells, in each of
the 16 holes, recorded (counts in 5min) the exploration of the holes
(exploratory activity) by the mice.
2.8. Cell cultures
Human cancer cell lines have been a useful tool for the study of the
molecular biology and therapy of cancer in many tumour types. Human
brain glioblastoma cancer cell, epithelial-like type as LN-229; human
brain likely glioblastoma cancer cell, epithelial-like type as U-87 MG,
were respectively grown in DMEM (Invitrogen, Paisley, UK) supple-
mented with 5% fetal bovine serum (FBS, Cambrex, Verviers, Belgium)
and in EMEM (Invitrogen, Paisley, UK) supplemented with 10% fetal
bovine serum (FBS, Cambrex, Verviers, Belgium), and both with L-
glutamine (2mM, Sigma, Milan, Italy), penicillin (100 units/ml, Sigma)
and streptomycin (100 μg/ml, Sigma), and cultured in a humidiﬁed 5%
carbon dioxide atmosphere at 37 °C, while human colon adenocarci-
noma cells Caco-2, was grown in Eagle's Minimum Essential Medium
(EMEM) supplemented with 20% fetal bovine serum (FBS, Cambrex,
Verviers, Belgium), and cultured in a humidiﬁed 5% carbon dioxide
atmosphere at 37 °C, according to ATCC recommendations. Human
HaCaT keratinocytes, used as healthy control cell lines, were grown in
DMEM (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine
serum (FBS, Cambrex, Verviers, Belgium), L-glutamine (2mM, Sigma,
Milan, Italy), penicillin (100 units/ml, Sigma) and streptomycin
(100 μg/ml, Sigma) and cultured in the same experimental conditions.
Moreover, Caco-2 cells, led to diﬀerentiation, were used at post-con-
ﬂuence stage as a model of human enterocytes [34].
2.9. Bioscreens in vitro
The activity of tanshinone IIA, cryptotanshinone and the extract of
Salvia miltiorrhiza was investigated through the estimation of a “cell
survival index” [35], obtained from the combination of the automated
cell count and the percentage values derived from the metabolic MTT
assay, as the arithmetic mean, providing a more accurate parameter of
the actual number of cells that survive after a preclinical study in vitro.
Cells were inoculated in 96-microwell culture plates at a density of 104
cells×well and allowed to grow for 24 h. The medium was then re-
placed with fresh medium and cells were treated for further 48 h with a
range of concentrations from 10 to 100 μM of TIIA and CRY, while a
range of concentrations from 10 to 100 μg/ml of Salvia miltiorrhiza
extract. Using the same experimental procedure, cell cultures were also
incubated with the vehicle DMSO as negative control. Cell viability was
evaluated using the MTT assay procedure, which measures the level of
mitochondrial dehydrogenase activity - using the yellow 3-(4,5-di-
methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT,
Sigma) as substrate - to convert dissolved MTT into insoluble purple
formazan. In short, after the treatments, the medium was removed and
the cells were incubated with 20 μl ×well of a MTT solution (5mg/ml)
for 1 h in a humidiﬁed 5% CO2 incubator at 37 °C. The incubation was
stopped by removing the MTT solution and by adding 100 μl/well of
DMSO to solubilize the obtained formazan. Finally, the absorbance was
monitored at 550 nm using a microplate reader (iMark microplate
reader, Bio-Rad, Milan, Italy). Cell number was determined by TC10
automated cell counter (Bio-Rad, Milan, Italy), providing an exact and
reproducible total count of cells and a live/dead ratio in one step by a
speciﬁc dye (trypan blue) exclusion assay. Bio-Rad’s TC10 automated
cell counter uses disposable slides, TC10 trypan blue dye (0.4% trypan
blue dye w/v in 0.81% sodium chloride and 0.06% potassium phos-
phate dibasic solution) and a CCD camera to count cells based on the
analyses of captured images. Once the loaded slide is inserted into the
slide port, the TC10 automatically focuses on the cells, detects the
presence of trypan blue dye and provides the count. When cells are
damaged or dead, trypan blue can enter the cell allowing living cells to
be counted. Operationally, after treatments in 96-microwell culture
plates, the medium was removed and the cells were collected. Ten
microliters of cell suspension, mixed with 0.4% trypan blue solution at
1:1 ratio, were loaded into the chambers of disposable slides. The re-
sults are expressed in terms of total cell count (number of cells per ml).
If trypan blue is detected, the instrument also accounts for the dilution
and shows live cell count and percent viability. Total counts and live/
dead ratio from random samples for each cell line were subjected to
comparisons with manual haemocytometers in control experiments.
The calculation of the concentration required to inhibit the net increase
in the cell number and viability by 50% (IC50) is based on plots of data
(n= 6 for each experiment) and repeated ﬁve times (total n= 30). IC50
values were obtained by means of a concentration response curve by
nonlinear regression using a curve ﬁtting program, GraphPad Prism 5.0,
and are expressed as mean values ± SEM (n= 30) of ﬁve independent
experiments.
2.10. Statistical analysis
The analysis of variance of the behavioural data was performed by
one way ANOVA, and a Bonferroni's signiﬁcant diﬀerence procedure
was used as post-hoc comparison, by using the “Origin 9” software
(OriginLab, Northampton, USA). In vitro data were analyzed using
Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA
test for multiple comparisons was performed followed by Bonferroni’s
test. All data were presented as mean values ± SEM. Values of P ≤
0.05 were considered statistically signiﬁcant. Investigators were blind
to all experimental procedures.
3. Results
3.1. Pain relief, acute treatments
The eﬀects of Salvia miltiorrhiza products against neuropathic pain
were studied in a mouse model of chemotherapy-induced neuropathy.
The neurotoxicity of oxaliplatin (OXA) was used to develop a neuro-
pathic syndrome characterized by thermal hypersensitivity after re-
peated (7 or 14 days) administrations (2.4 mg/kg, intraperitoneally)
[31,32]. On day 14, the response to a cold non-noxious stimulus (al-
lodynia-like symptom) was measured by the Cold plate test. The pain
threshold of OXA-treated animals decreased to 9.5 ± 0.2 s in com-
parison to control, vehicle-treated animals (18.7 ± 0.2 s). A single
administration per os (p.o.) of cryptotanshinone (CRY) at 30mg/kg was
able to signiﬁcantly increase the pain threshold of OXA-treated mice.
The onset was 15min after treatment lasting for 45min, at 30min
neuropathic pain was fully reverted (Fig. 1a). The lower dose (10mg/
kg) was ineﬀective. In the same condition, tanshinone IIA (TIIA; 10 and
30mg/kg p.o.) did not show eﬀect against pain (Fig. 1b). As shown in
Fig. 1c, the extract from Salvia miltiorrhiza roots, Danshen, induced a
dose-dependent pain-relieving eﬀect. Danshen (titled as 1% tan-
shinones) dosed at 300 and 600mg/kg signiﬁcantly increased the pain
threshold. The higher dose was active between 15 and 45min peaking
at 30min when the hypersensitivity was completely abolished (Fig. 1c).
3.2. Pain relief, repeated treatments
The pain-relieving proﬁles of tanshinones were also studied after a
repeated administration. CRY and TIIA (10mg/kg) were administered
daily p.o. in OXA-treated mice starting from the ﬁrst day of OXA in-
jection. On day 7, 24 h after the last administration, both CRY- and
TIIA-treated mice showed a signiﬁcantly increased pain threshold
(Fig. 2). A new administration of compounds to the repeatedly treated
animals did not improve pain relief (data not shown). In conclusion, a
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subchronic treatment was able to increase potency and eﬃcacy of both
compounds. In particular, the eﬀects of TIIA were unmasked. Im-
portantly, the pain-relieving eﬀect after a repeated treatment was long
lasting and the possibility of tolerance development was excluded.
3.3. Motor and neurological evaluations
The safety of tanshinones was evaluated measuring the locomotor
and exploratory activities (Hole board test) as well as the motor co-
ordination (Rota rod test) in OXA-treated mice. As shown in Table 1,
OXA did not alter nor locomotor neither exploratory activities. On day
7, both CRY and TIIA did not modify these parameters 30min after a
single administration to OXA-treated animals. Moreover, measurements
were performed also after a repeated treatment (daily starting from the
ﬁrst day of OXA treatment). On day 7, 24 h after the last administration
of compounds, CRY and TIIA did not modify the performances in
comparison to OXA per se and vehicle. On day 14, the acute and re-
peated administrations of TIIA and the acute CRY were safe whereas the
repeated administration of CRY signiﬁcantly decreased the locomotor
and exploratory activities (Table 1). Motor coordination skills after
repeated treatment are shown in Table 2. On day 7, the time spent on a
rotating rod was not modiﬁed nor by OXA neither by CRY or TIIA. On
day 14, OXA reduced the coordination (150.8 ± 20.3 s) in comparison
to control (278.5 ± 45.0 s). The co-administration with TIIA did not
alter OXA eﬀect, CRY basically (P=0.066) worse OXA eﬀect (Table 2).
3.4. Cytotoxic activity of tanshinones
Tanshinone IIA (TIIA) and cryptotanshinone (CRY) were examined
Fig. 1. Eﬀect of cryptotanshinone (CRY), tanshinone (TIIA), and Salvia mil-
tiorrhiza root extract (Danshen) on oxaliplatin-induced neuropathic pain in
mice. Oxaliplatin (2.4 mg/kg) was administered (i.p.) during days 1-3, 5-9, and
12-13, and the subsequent neuropathic pain determined by using the cold plate
test. On day 14, a) CRY, b) TIIA, and c) Danshen were administered (p.o.), and
their anti-neuropathic pain activity subsequently determined. The time latency
(in seconds) for the ﬁrst signs of pain-related behavior (i.e., lifting and licking of
the hind paw) was recorded after 15, 30, 45, and 60min. The plots are re-
presentative of 10 mice analyzed in 2 diﬀerent experimental sets, the error bars
are the SEM. The post hoc Bonferroni’s was performed. **P< 0.01 vs ve-
hicle+ vehicle treated animals; ^^P< 0.01 vs OXA+vehicle treated animals.
Fig. 2. Anti-neuropathic pain activity of cryptotanshinone (CRY) and tan-
shinone (TIIA) after repeated treatment. Mice were treated (i.p.) with 2.4mg/
kg oxaliplatin following the described protocol. Starting from the ﬁrst day of
oxaliplatin treatment, CRY and TIIA were daily administered p.o.. On day 7,
24 hours after the last injection, pain threshold was determined by the cold
plate test and compared to that for vehicle+ vehicle treated animals. Results
are the mean of 10 animals analyzed in 2 diﬀerent experimental sets, the error
bars are the SEM. The post hoc Bonferroni’s was performed. **P<0.01 vs
vehicle+ vehicle treated animals; ^^P<0.01 vs OXA+vehicle treated ani-
mals.
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for their cytotoxic activities against several tumor and normal human
cell lines (LN-229; U-87 MG, Caco-2, HaCaT and human enterocytic cell
lines). Both TIIA and CRY revealed a strong and broadly similar anti-
proliferative/cytotoxic activity on all cancer cell lines used, in a dose-
dependent way (Fig. 3). In particular, this eﬀect was very signiﬁcant on
LN-229 and U-87 MG glioblastoma cells. The concentration-eﬀect
curves (Fig. 3)- here reported in terms of a “cell survival index” - show a
typical concentration-dependent sigmoid trend achieving IC50 values in
the low micromolar range. Indeed, according to the IC50 values (see
Table 3), the tanshinone IIA and cryptotanshinone reduce the pro-
liferation of all the used cancer cell lines, while they are not so cytotoxic
against the used healthy cell lines.
3.5. Cytotoxic activity of Salvia extract
The activity of the extract of Salvia miltiorrhiza (rich in tanshinones)
[14] was studied for the cell growth-inhibitory activity against cancer
and normal human cell lines LN-229, U-87 MG and HaCaT. As shown by
graphs (Fig. 4), Salvia extract revealed a very strong antiproliferative
activity on both cancer cell lines used, in a dose-dependent way and in
particular by using the two highest concentrations. Noteworthy, the
antiproliferative activity is not so prominent on the used healthy cells
HaCaT, as demonstrated by IC50 values (Table 3). Overall, these results
suggest that tanshinones display a high antiproliferative activity in vitro
assays against human tumor cells.
4. Discussion
Oxaliplatin, a third-generation platinum derivative, is one of the
most eﬀective chemotherapeutic drugs used to treat advanced (espe-
cially colorectal) cancer [36]. However, it is associated with the de-
velopment of neurotoxicity, which is one of the most prevalent and
dose-limiting eﬀects that includes mechanical allodynia and hy-
persensitivity to cold [37,38]. Although oxaliplatin-induced neuro-
pathy has been studied for several years, no eﬀective therapy against its
side eﬀects are currently available.
As a result, some patients have utilized or expressed interest in
complementary medicine (in particular to phytomedicine and nu-
traceutical) for disease prevention and/or enhancing quality of life. In
this context the search on phytomedicine-based therapy could represent
a steady coadjuvant approach [8,39,40]. Even if there is a rigorous
debate about the real eﬀect of these compounds on human health it has
been diﬃcult to reliably show beneﬁcial eﬀects of speciﬁc phyto-
complex or nutraceuticals on cancer treatment [41].
Our study reveals that Salvia miltiorrhiza root extract (Danshen) and
its main active lipophilic components TIIA and CRY attenuate in vivo
the oxaliplatin-induced nociceptive hypersensitivity and proposes their
selective inhibitory activities on glioblastoma cells lines. We speculate
that these ﬁndings may provide a beneﬁcial choice for oxaliplatin
neuropathy treatment in the continuing expanding context of phyto-
medicine.
In order to test whether Danshen and its main constituents were
eﬀective in attenuating oxaliplatin-induced peripheral neuropathy, we
designed a neurotoxicity model using male CD-1 albino mice.
Consistent with our previous reports [42,32], hypersensitivity to me-
chanical and thermal stimuli was progressively increasing over time
reaching signiﬁcant values after 1 and 2 weeks of treatment when the
cumulative dose of oxaliplatin injected is clinically relevant for neu-
ropathy development [43]. On day 14, oxaliplatin-dependent cold al-
lodynia was dose-dependently prevented by a single oral administration
of Danshen and its related active component CRY. On the contrary, TIIA
was inactive after a single administration. Nevertheless, a repeated
daily administration was able to unmask the activity of TIIA and to
show the maintenance of CRY eﬃcacy. The presence of signiﬁcant pain
relieving eﬀects after several days of treatment suggest the possibility of
a long-term treatment without decrease of eﬃcacy.This is of pivotal
importance considering the need of chronic treatments for this kind of
persistent pain, a reason why the classical analgesic compounds like
opioid are unsatisfactory [44].
To validate the data, the safety proﬁle of tanshinones was evaluated
by measuring the locomotor and exploratory activities as well as the
motor coordination. Both compounds after a single treatment did not
induce motor or neurological alterations. The complete absence of be-
havioral alterations was conﬁrmed also on day 7, after 6 days of re-
peated administration. To note, on day 14 after 13 days of treatment a
Table 1
Eﬀect of acute (a) and repeated (c) administration of cryptotanshinone and tanshinone IIA on locomotor and exploratory activities in mice. Hole board test.
Treatments Dose
mg/ kg
Day 7 Day 14
Hole Board Hole Board
vehicle+ vehicle 40.3 ± 5.6 75.6 ± 6.4 42.0 ± 4.0 80.7 ± 7.3
OXA+vehicle 50.2 ± 10.2 82.3 ± 4.6 44.8 ± 5.0 70.3 ± 8.6
OXA+CRY (a) 30 42.6 ± 4.4 70.9 ± 8.9 39.9 ± 3.7 85.3 ± 12.9
OXA+CRY (r) 10 40.8 ± 5.2 84.3 ± 7.8 18.5 ± 3.7* 27.0 ± 4.9*
OXA+TIIA (a) 30 45.8 ± 3.2 75.6 ± 7.4 42.6 ± 5.8 67.9 ± 8.1
OXA+TIIA (r) 10 42.9 ± 2.9 70.6 ± 5.5 33.2 ± 8.3 67.8 ± 7.6
Oxaliplatin (2.4 mg/kg) was repeatedly administered over 2 weeks. The eﬀects of tanshinone IIA (TIIA) and cryptotanshinone (CRY) were evaluated acutely (a)
30min after a single administration p.o. on days 7 and 14 of oxaliplatin treatment. Measurements were performed also after a repeated (r) treatment; starting from
the ﬁrst day of oxaliplatin treatment, TIIA and CRY were daily administered p.o. for 14 days, behavioral measurements were performed 24 h after the last ad-
ministration of compounds. The Hole board test was performed measuring the spontaneous mobility (board) and the exploratory activity (hole) of mice were
automatically recorded. Each value represents the mean of 10 mice analyzed in 2 diﬀerent experimental sets,± SEM. *P< 0.05 vs vehicle+ vehicle treated animals.
Table 2
Eﬀect of repeated administration of cryptotanshinone and tanshinone on motor
coordination in mice. Rota rod test.
Treatments Dose
mg kg
Day 7 Day 14
Time (s) Time (s)
vehicle+ vehicle 296.4 ± 29.2 278.5 ± 45.0
OXA+vehicle 249.8 ± 30.7 150.8 ± 20.3*
OXA+CRY 10 275.4 ± 33.8 95.7 ± 10.7*
OXA+TIIA 10 267.9 ± 26.5 186.8 ± 20.1*
Oxaliplatin (2.4 mg/kg) was repeatedly administered over 2 weeks. The eﬀects
of tanshinone IIA (TIIA) and cryptotanshinone (CRY) were evaluated after a
repeated treatment. Starting from the ﬁrst day of oxaliplatin treatment, CRY
and TIIA were daily administered p.o. for 14 days, behavioral measurements
were performed on days 7 and 14, 24 h after the last administration. The in-
tegrity of motor coordination was assessed on the basis of the time the animals
kept their balance on the rotating rod for a maximum of 10min (600 s). After a
maximum of 6 falls from the rod the test was suspended and the time was
recorded. Each value represents the mean of 10 mice analyzed in 2 diﬀerent
experimental sets,± SEM. *P< 0.05 vs vehicle+ vehicle treated animals.
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cumulative toxicity of CRY (when added to OXA dosing) appeared. TIIA
was safe at both time point.
The eﬃcacy of Danshen and its constituents, tanshinones, against neu-
ropathic pain is consistent with previously published data that describe
tanshinones (in particular TIIA) as potent monoacylglycerol lipase (MAGL)
inhibitor [45]. MAGL is the main metabolic enzyme involved in the in-
activation of the endocannabinoid 2-arachidonoylglycerol (2-AG), the in-
hibition of this serine hydrolase increases endocannabinoid levels evoking
pain relief [46,47]. Accordingly, TIIA was also eﬀective in reducing visceral
and somatic persistent pain in rats [48]. Of particular interest is also the
obtained results on our bioscreens in vitro aimed to investigate the tan-
shinone's cytotoxic eﬀect on diﬀerent tumor cell lines. Our results showed
that both TIIA and CRY possess a strong cytotoxic activity, particularly on
LN-229 and U-87 MG glioblastoma cells. This would suggest a possible
selectivity of action. These observations have been summarized also by
analyzing the IC50 values shown in Table 3, where both TIIA and CRY
Fig. 3. Cell survival index: evaluated by the MTT assay and monitoring of live/dead cell ratio for A human brain glioblastoma cancer cell, LN-229; B human brain
likely glioblastoma cancer cell, U-87 MG; C human colon adenocarcinoma cancer cell, Caco-2, D human HaCaT keratinocytes and E human enterocytic cells,
following 48 h of incubation with a speciﬁc range of concentration (10 – 100 μM) of Tanshinone IIA (TIIA) and Cryptotanshinone (CRY), as indicated in the legend.
Data are expressed as percentage of untreated control cells and are reported as mean of ﬁve independent experiments ± SEM (n=30).
Table 3
IC50 values relative to the TIIA, CRY (μM) and Salvia miltiorrhiza extract (μg/
mL) in the cancer and healthy cell lines.
TIIA CRY Salvia
LN-229 48.2 ± 4.9 51.9 ± 2.3 50.0 ± 4.0
U-87 MG 48.6 ± 3.1 50.0 ± 4.2 53.8 ± 2.0
Caco-2 98.0 ± 1.5 < 100 n.a.
HaCaT <100 97.2 ± 2.0 86.0 ± 4.0
Enterocytes < 250 <250 n.a.
IC50 values relative to the TIIA, CRY (μM) and Salvia miltiorrhiza extract (μg/
mL) in the cancer cell lines (LN-229, U-87 MG and Caco-2) and human healthy
cells (HaCaT and enterocytes) following 48 h of incubation. The values are
reported as mean values ± SEM (n=30). (n.a. = not assessed).
Fig. 4. Salvia extract activity. Cell survival index, evaluated by the MTT assay and monitoring of live/dead cell ratio for A human brain glioblastoma cancer cell, LN-
229; B human brain likely glioblastoma cancer cell, U-87 MG and C human HaCaT keratinocytes, following 48 h of incubation with a speciﬁc range of concentration
(10 – 100 μg/ml) of extract of Salvia miltiorrhiza. Data are expressed as percentage of untreated control cells and are reported as mean of ﬁve independent
experiments ± SEM (n=30).
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present higher IC50 values on human colon adenocarcinoma cells Caco-2
than on LN-229 and U-87 MG glioblastoma cancer cell lines.
Our results are in accordance with related studies that have in-
dicated a role of tanshinones in the inhibition of cancer growth by in-
duction of apoptosis [49,50]. Thus, it was reasonable to speculate if
tanshinones would play an important role in the inhibition of glio-
blastoma cell lines. The cellular and molecular changes underlying
neuroblastoma development and progression remain poorly under-
stood; however, the nuclear factor-κB (NFκB) transcription factor seem
to inﬂuence both neuroblastoma survival and cell death [51,52]. Ac-
cordingly, we and other have recently demonstrated that tanshinones
TIIA and CRY selectively interfere with NFκBp65 expression (with a
specular and signiﬁcant modulation of IKBα) in the CNS [16] and that
these compounds seem to be similar as anticancer agents to emodin in
terms of inhibition of neuroectodermal tumors [53,54,55,56].
On the other hand, there were still many details yet unknown about
the primary mechanism of the suppression of glioblastoma by tan-
shinones, and for this reason it was necessary to validate whether these
compounds exhibited toxicity and if there was the presence of any by-
eﬀects on normal human cells. To this aim, we have tested the eﬀect of
Danshen, CRY and TIIA on human HaCaT keratinocytes and human
enterocytic cell lines. Our results showed that they do not signiﬁcantly
reduce the proliferation of tested healthy cell lines.
5. Conclusion
As a whole, we demonstrated for the ﬁrst time that herbal medicine
Danshen ameliorated the oxaliplatin-induced neuropathy in the mouse
model of oxaliplatin-induced nociceptive hypersensitivity. Moreover,
we have also shown its selective inhibitory activities on glioblastoma
cells lines. Based on our results, we contribute a plausible explanation
and the opportunity for the evaluation of Danshen (and its active
constituents TIIA and CRY), in the treatment or combination therapy of
oxaliplatin–associated neuropathy. Undoubtedly, there were some
limitations in our study. The exact mechanisms responsible for the
neuroprotective eﬀects of these natural compounds are still unknown
and also a long-term study is needed to further conﬁrm our results.
Thus, there is an urgent need to carry out further experiments to es-
tablish a precise foundation for the application of this plant extract as a
new potential source of active diterpenoidic compounds useful for
pharmaceutical and/or nutraceutical industries.
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